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80Objective: The study objective was to evaluate the association between timing of intraaortic balloon pump in-
sertion and outcomes in patients undergoing cardiac surgery.
Methods: All patients aged 18 years or more who underwent coronary artery bypass surgery, cardiac valve sur-
gery, or thoracic aortic surgery between January 2002 and December 2007 were included. Data were obtained from
cardiac surgery and intensive care databases. Patients were categorized as receiving a preoperative, intraoperative,
or postoperative intraaortic balloon pump and compared with a reference group who did not receive an intraaortic
balloon pump. Summary and descriptive statistics were used to compare the groups. Logistic regression was used
to model in-hospital mortality, and survival methods were used to model time to event data, such as length of stay.
Results: There were 7440 patients included over a 6-year period, of whom 217 (2.9%) received a preoperative
intraaortic balloon pump, 184 (2.4%) received an intraoperative intraaortic balloon pump, and 42 (0.56%) re-
ceived a postoperative intraaortic balloon pump. Logistic European System for Cardiac Operative Risk Evalu-
ation–derived predicted risk of death was higher across all intraaortic balloon pump groups compared with the
group with no intraaortic balloon pump. Observed in-hospital mortality was significantly lower in the preopera-
tive group (10%) and the group with no intraaortic balloon pump (0.8%) compared with the intraoperative (16%)
and postoperative (29%) groups. Risk-adjusted mortality was also lower in the preoperative group.
Conclusion: This study comparing outcomes in patients undergoing cardiac surgical procedures with timing of
intraaortic balloon pump placement revealed that the use of preoperative intraaortic balloon pumps was associated
with a strong trend toward reduction in in-hospital mortality despite a higher predicted mortality in this group. The
study provides support to the growing body of literature advocating preoperative use of intraaortic balloon pumps
in carefully selected patients. (J Thorac Cardiovasc Surg 2010;140:80-5)The intraaortic balloon pump (IABP) is the most commonly
used mechanical support method in cardiac surgery. It im-
proves diastolic coronary blood flow, reduces left ventricular
afterload, and enhances endomyocardial perfusion. IABPs
are reported to be used in 5% to 10% of cardiac surgical
cases.1,2 Insertion practices vary, with the Benchmark Reg-
istry and Society of Thoracic Surgeons database showing
that 52.4% and 63.5%, respectively, are inserted preopera-
tively.3,4 Practices in Europe differ from the United States,
with approximately 40% to 45% inserted preoperatively ac-
cording to a large European study.5 In our center, we have
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The Journal of Thoracic and Cardiovascular Surgesignificant differences between Australian and European
cardiac surgical populations and lack of local, large studies
make a formal evaluation of preoperative IABP utility im-
perative.8
The role of the preoperative prophylactic IABP is subject to
debate. Dyub and colleagues9 recently performed a meta-anal-
ysis of randomized controlled trials and cohort studies that
showed lower mortality and hospital length of stay in the pre-
operative group. The largest and only multicenter study in that
analysis showed no survival advantage with preoperative in-
sertion in stable patients undergoing coronary artery bypass
surgery versus intraoperative insertion as required, although
postoperative length of hospital stay was reduced in the preop-
erative insertion cohort.10 The inclusion and exclusion criteria
vary between studies, limiting generalizability, and the authors
discussed limitations and potential biases of the study, includ-
ing small patient numbers, lack of multicenter studies, and var-
iability in criteria for insertion.
It is widely recognized that the cardiac surgical patient is
undergoing more complex surgery and that the incidence of
isolated coronary artery bypass grafting (CABG) is decreas-
ing, whereas that of combined valve plus CABG surgery is
increasing. Controversy still exists as to the optimal timingry c July 2010
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
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quire an IABP and who can be managed without one. Con-
cerns remain surrounding the increased use of preoperative
IABPs, because complications, although rare, may be life-
threatening. These can include major vascular, limb ische-
mia, and bleeding complications.11
In light of these factors, the aim of this study was to re-
view the timing of IABP insertion and outcomes in an unse-
lected cardiac surgical sample. We analyzed outcomes
adjusting for known risk factors and determined clinical
and operative risk factors for intraoperative and postopera-
tive insertion.MATERIALS AND METHODS
This study was performed at The Prince Charles Hospital, a 450-bed ter-
tiary referral, university-affiliated, teaching hospital with a predominantly
cardiothoracic patient case mix. Data were obtained from the cardiac sur-
gery and intensive care databases. The patients included were those who un-
derwent coronary artery bypass surgery, cardiac valve surgery, or aortic
surgery between January 2002 and December 2007. Patients were excluded
if they were aged less than 18 years or were undergoing transplant, ventric-
ular assist device, pulmonary thromboendarterectomy, or adult congenital
heart surgery. Data were collected by trained data collectors, and data qual-
ity was maintained by several processes, including edit checks (built into the
database) and scheduled data cleaning. All cardiac surgeons were sent a re-
port on surgical outcomes for their individual patients before each monthly
audit for confirmation of accuracy and completeness. All missing fields
were treated as the variable being absent, and no imputations were used.
The primary outcome measure was in-hospital mortality. Secondary out-
come measures were duration of ventilation in the intensive care unit (ICU),
length of stay in the ICU, and length of hospital stay.
Patients were categorized depending on the timing of IABP placement.
The control group included patients who did not receive an IABP. The pre-
operative group included patients who had an IABP placed before surgical
skin incision. The intraoperative group included patients in whom the IABP
was placed after skin incision but before leaving the operating room. The
postoperative group included patients who received an IABP after leaving
the operating room of the primary operation. Preoperative IABPs were
usually placed in the pre-theater setting (cardiac catheterization laboratory,
interhospital transfer, or intensive care in rare cases), and the common insti-
tutional indications were critical left main stem coronary disease, cardio-
genic shock after acute myocardial infarction or unstable angina,
mechanical complications of acute myocardial infarction (ie, acute mitral re-
gurgitation, and ventricular septal defect).
The decision to place an IABP intraoperatively or postoperatively was at
the discretion of the operating surgeon. Common indications were difficulty
or inability to separate from bypass and unanticipated intraoperative or post-
operative complications.
Data collected included demographic, clinical, and outcome data. Unless
otherwise specified, variables were defined as used in the European SystemThe Journal of Thoracic and CforCardiacOperativeRiskEvaluation (EuroSCORE).12 Clinical and demo-
graphic variables were compared across all patient categories, with the Krus-
kal–Wallis test for continuous variables and the chi-square test of general
association for categoric variables. Risk adjustment for outcomes used pre-
operative and intraoperative variables. Potential confounding exists because
EuroSCORE defines critical preoperative state as a requirement for preoper-
ative balloon pump. Because this is potentially a subjective decision, analy-
sis was preformed with and without this variable as a risk factor.
The association between timing of IABP insertion and in-hospital mor-
tality was modeled using logistic regression, controlling for known predic-
tors of risk in cardiac surgery. A second model was developed to determine
predictors of the need for an intraoperative or postoperative IABP using pre-
operative variables. Standard diagnostic methods were used to assess model
performance with analysis of calibration and discrimination. Test of trend
was applied to determine the trend of IABP use over the 6-year study period.
No funding agency was involved in the study, and administrative staff sup-
port was provided by Critical Care Research Group. The study received ap-
proval of the Ethics Committee of the institution before its conduct.RESULTS
There were 7440 patients included in the study, of whom
443 (5%) received an IABP. The characteristics of the sam-
ple are shown in Table 1. In this sample, 217 patients (2.9%)
received a preoperative IABP, 184 patients (2.5%) received
an intraoperative IABP, and 42 patients (0.6%) received
a postoperative IABP. Compared with the intraoperative or
postoperative group, the preoperative group was more likely
to undergo CABG only, undergo emergency surgery, be in
a critical preoperative condition, and have preoperative un-
stable angina or a recent myocardial infarction. The intrao-
perative group was more likely to undergo more complex
surgery and reoperation surgery, and have vascular disease
and pulmonary hypertension. There was no difference be-
tween the groups with regard to age and ventricular function.
A greater percentage of female patients received postopera-
tive IABPs. Female gender and vascular disease are known
higher risk factors for ischemic limb complications and may
reflect the practice of deferring or avoiding ‘‘prophylactic’’
IABP placement in high-risk candidates until it becomes
clear it is clinically indicated (eg, to separate from cardiopul-
monary bypass). Table 1 shows that most patients with left
main coronary disease (1265/1428 ¼ 86%), 3-vessel coro-
nary disease (3697/3892 ¼ 95%), poor ejection fraction
(163/249 ¼ 65%), unstable angina (152/238 ¼ 64%), or re-
operation (759/832 ¼ 91%) did not receive an IABP.
The changes in practice over time are shown in Table 2.
During the study period, there was a trend to increased pre-
operative and total IABP use (test for trend P<.01), the ex-
ception being years 2004 and 2005, when intraoperative and
postoperative use was higher compared with other years, but
declined again subsequently. This could be attributed to
changes in surgical personnel or the preferences of the oper-
ating surgeon/s at these time points.
Table 3 shows the outcomes during the study period. The
overall mortality was 1.6%: 0.8% in the control group,
9.7% in the preoperative group, 15.8% in the intraoperativeardiovascular Surgery c Volume 140, Number 1 81
TABLE 1. Patient characteristics by timing of intraaortic balloon pump insertion
No IABP N ¼ 6997 Preoperative N ¼ 217 Intraoperative N ¼ 184 Postoperative N ¼ 42
Variable
Mean age (SD y) 64 (12) 65 (11) 66 (11) 65 (13)
Gender (female%) 1995 (29) 58 (27) 49 (27) 19 (45)
Serum creatinine (SD, mmol/L) 100 (50) 120 (98) 120 (61) 130 (72)
Creatinine>200 mmol/L (%) 169 (2.4) 19 (9) 9 (5) 8 (19)
Vascular disease (%) 960 (14) 19 (9) 33 (18) 7 (17)
Chronic pulmonary disease (%) 957 (14) 41 (19) 35 (19) 9 (21)
Neurological dysfunction (%) 108 (2) 7 (3) 5 (3) 2 (5)
Ejection fraction<30% (%) 163 (2) 43 (20) 39 (21) 4 (10)
Ejection fraction 30%–50% (%) 1296 (19) 73 (34) 60 (33) 16 (38)
Critical preoperative state (%) 86 (1) 202 (93) 17 (9) 5 (12)
Unstable angina (%) 152 (2) 52 (24) 20 (11) 4 (10)
Recent MI (%) 1428 (20) 153 (71) 73 (40) 13 (31)
Elective (%) 4571 (65) 9 (4) 74 (40) 17 (40)
Urgent (%) 2321 (33) 110 (51) 94 (51) 20 (48)
Emergency or salvage surgery (%) 105 (2) 98 (45) 16 (9) 3 (12)
Reoperation (%) 759 (11) 8 (4) 56 (30) 9 (21)
Endocarditis (%) 144 (2) 3 (1) 8 (4) 3 (7)
Pulmonary hypertension (%) 378 (5) 18 (8) 27 (15) 8 (19)
Post-infarct VSD (%) 1 (0.01) 6 (3) 2 (1) 0 (0)
Left main>50% (%) 1265 (18) 111 (51) 42 (23) 10 (24)
3 vessels (%) 3697 (53) 161 (74) 11 (65) 23 (55)
2 vessels (%) 1184 (17) 39 (18) 26 (14) 8 (19)
1 vessel (%) 518 (7) 8 (4) 8 (4) 0
No coronary disease (%) 1598 (23) 9 (4) 31 (17) 10 (26)
Preoperative ventilation (%) 40 (0.6) 30 (14) 4 (2) 2 (5)
Logistic EuroSCORE risk of death (%) 6.4 23.6 16.1 17
Aortic wall (%) 409 (6) 0 13 (7) 4 (10)
CABG only (%) 4202 (60) 159 (73) 83 (45) 19 (45)
1 valve (%) 1133 (16) 8 (4) 12 (7) 4 (10)
1 valveþCABG (%) 789 (11) 33 (15) 44 (24) 6 (14)
Aortic or complex surgery (%)* 873 (12) 17 (8) 45 (24) 13 (31)
CABG, Coronary artery bypass grafting; EuroSCORE, European System for Cardiac Operative Risk Evaluation; IABP, intraaortic balloon pump; MI, myocardial infarction; SD,
standard deviation; VSD, ventricular septal defect. Figures in brackets indicate percentages unless indicated otherwise. *Complex surgery is defined as surgery on 2 or more cardiac
valves with or without CABG. Aortic surgery is any surgery involving ascending aorta, aortic arch, or proximal descending thoracic aorta.
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pulmonary bypass times were substantially longer in the in-
traoperative group. Intensive care, postoperative, and
mechanical ventilation times were longer in the intraopera-
tive and postoperative groups. When risk adjusted, the in-
hospital mortality was significantly lower in the preoperative
and the ‘‘no IABP’’ group than the predicted logistic Euro-
SCORE risk of death (preoperative 9.7% vs 23.6%; no
IABP 0.8% vs 6.4%). Although it was comparable to the
predicted mortality in the intraoperative group (15.8% vs
16.1%), the postoperative group had a higher than predicted
mortality (28.6% vs 17%).
Table 4 shows the univariate and multivariate logistic re-
gression models for in-hospital mortality. The unadjusted
mortality shows that preoperative insertion has a lower mor-
tality than intraoperative insertion. When controlling for risk
of death using EuroSCORE, preoperative insertion was as-
sociated with a significantly lower mortality compared82 The Journal of Thoracic and Cardiovascular Surgewith intraoperative and postoperative insertion. The odds ra-
tio for death is 0.3 (0.15–0.61) for preoperative compared
with intraoperative insertion. The effect is smaller, but there
is a trend to reduced mortality when a locally derived risk
adjustment model is used. The odds ratio for death is 0.51
(0.23–1.1) for preoperative compared with intraoperative
insertion. When cardiopulmonary bypass time is included,
there is no statistically significant difference between preop-
erative and intraoperative insertion. Postoperative insertion
remains associated with increased mortality regardless of
the risk adjustment method.
The strongest overall predictor was cardiopulmonary by-
pass time with an odds ratio of 1.01 (95% confidence inter-
val, 1.01–1.02) per minute. Cardiopulmonary bypass time
indicates total combined bypass time, including multiple at-
tempts to separate from bypass. When cardiopulmonary by-
pass time was included, reoperation, poor left ventricular
function, increased creatinine, recent myocardial infarction,ry c July 2010
TABLE 2. Trends in timing of intraaortic balloon bump insertion over the past 6 years
Year No IABP Preoperative (%) Intraoperative (%) Postoperative (%) IABP total (%)
2002 1383 29 (2) 27 (2) 4 (0.3) 60 (4.3)
2003 1206 23 (2) 29 (2.5) 5 (0.4) 57 (5)
2004 1231 36 (3) 39 (3) 14 (1) 89 (7)
2005 1147 39 (3.4) 45 (4) 9 (0.8) 93 (8)
2006 1036 41 (4) 26 (2.5) 3 (0.3) 70 (7)
2007 994 49 (5) 18 (1.8) 7 (0.7) 74 (7.4)
Total 6997 217 184 42 7440
IABP, Intraaortic balloon pump. Test for difference in numbers and timing of insertion between years: Pearson chi-square (15) ¼ 47.4214, P< .001.
Lavana et al Acquired Cardiovascular Disease
A
C
Dpulmonary hypertension, and unstable angina remain statis-
tically significant.
Figure 1 shows postoperative length of stay in the groups
in the sample stratified by timing of IABP insertion. This
graph shows a substantially skewed distribution of length
of stay and early deaths resulting in a shorter length of
stay. Overall, the postoperative group had the longest venti-
lation times and ICU and hospital stays. The preoperative
group had a lower median duration of ventilation (24 vs
36 hours), lower ICU stay (69 vs 90 hours), and borderline
lower postoperative hospital length of stay (10 vs 12 days)
compared with the intraoperative group. When allowance
was made for multiple comparisons, the preoperative group
showed statistically significantly shorter ICU hours than the
intraoperative group.
Table 5 shows the predictors of use of an intraoperative or
postoperative IABP using preoperative factors and exclud-
ing those who had a preoperative IABP. Table 5 shows
that in addition to well-described risk factors (poor ejection
fraction, reoperation, and unstable angina), recent myocar-
dial infarction, renal dysfunction, pulmonary hypertension,
and complex surgery were associated with the requirement
for an intraoperative or postoperative IABP.
DISCUSSION
This study of 7440 cardiac surgical patients showed in-
creasing use of IABP and a trend to preoperative insertion
over time. It also demonstrated a lower crude mortality
with a trend to lower risk-adjusted mortality after preopera-TABLE 3. Relationship between timing of intraaortic balloon pump inser
No IABP
Intraoperative variables
Median CPB time with IQR (min)* *85 (67–112)
Outcomes
In-hospital mortality (%) 59 (0.8)
Median ventilation hours (IQR)y y9 (7–14)
Median ICU LOS hours (IQR)y 24 (21–42)
Reventilation (%) 201 (3)
Median postoperative hospital
LOS days (IQR)
8 (7–10)
CPB, Cardiopulmonary bypass; IABP, intraaortic balloon pump; ICU, intensive care unit;
IABP, 215 preoperative, 184 intraoperative, and 42 postoperative). yn ¼ 7414 (consisting
The Journal of Thoracic and Ctive compared with intraoperative insertion of IABP. The
findings were affected by the risk-adjustment method used
and confounded by the duration of cardiopulmonary bypass
time. The group that required a postoperative IABP had
a higher than expected mortality regardless of risk adjust-
ment method.
The strength of our study is that the number of patients
evaluated is large. Data were collected prospectively using
standardized forms by trained personnel. Outcome measures
were clearly defined (in-hospital mortality, hospital and ICU
length of stay, ventilation hours, and complications). Logis-
tic EuroSCORE was used to predict the risk of death and
compared with the observed mortality.
The limitation of this study is that it is not a randomized
study but a single-center retrospective analysis of prospec-
tively collected data. Potential confounding may also exist,
which is difficult to control for in such a study. However,
in keeping with the previous research in this area, we have
attempted to control for the confounding by comparing the
observed mortality with predicted risk of death from the
EuroSCORE. It may be suggested that the IABP itself, rather
than the disease process, dictates the emergency of the pro-
cedure, rather than the disease per se. However, detailed ex-
amination of our data indicates that the patients receiving
a preoperative balloon were indeed sicker, as indicated by
a higher number fulfilling the critical preoperative state cri-
teria and having a significantly higher logistic risk of death
compared with intraoperative or postoperative groups, re-
gardless of IABP status.tion, operative characteristics, and outcomes
Preoperative Intraoperative Postoperative
93 (70–126) 134 (105–188) 114 (81–167)
21 (10) 29 (16) 12 (29)
24 (17–68) 36 (21–88) 99 (35–214)
69 (45–120) 90 (62–152) 155 (74–447)
19 (9) 18 (10) 11 (26)
10 (8–18) 12 (9–19) 17 (10–36)
LOS, length of stay; IQR, interquartile range. *n ¼ 7200 (consisting of 6759 with no
of 6980 with no IABP, 214 preoperative, 178, intraoperative, and 42 postoperative).
ardiovascular Surgery c Volume 140, Number 1 83
TABLE 4. Relationship between timing of intraaortic balloon pump insertion and in-hospital mortality
Univariate
Multivariate adjusting
for EuroSCORE
Multivariate using
preoperative variables
Multivariate using preoperative variables and with
adjustment for cardiopulmonary bypass time
No IABP 1 1 1 1
Preoperative 12.6 (7.5–21) 3.9 (2.1–7.1) 5.9 (3–12) 5 (2.5–10)
Intraoperative 22 (13.7–55) 12.6 (7.5–21.1) 11.5 (6.7–20) 6.5 (3.6–12)
Postoperative 47 (23–96) 30.4 (14.4–68) 26 (11–60) 22 (9–52)
Model properties
Hosmer-Lemeshow
goodness-of-fit
N/A P ¼ .01 P ¼ .48 P ¼ .23
ROC 0.73 0.9 0.9 0.91
EuroSCORE, European System for Cardiac Operative Risk Evaluation; IABP, intraaortic balloon pump; ROC, receiver operating characteristic; N/A, not available. Cells show
odds ratio and 95% confidence interval (in brackets). No IABP insertion is the reference group unless otherwise specified. Preoperative variables included were age, gender, vas-
cular disease, reoperation, chronic obstructive pulmonary disorder, neurologic dysfunction, ejection fraction<30%, ejection fraction 30%–50%, serum creatinine, complexity of
surgery, and preoperative mechanical ventilation. The Hosmer-Lemeshow goodness-of-fit test was not appropriate for the univariate analysis because there were only 2 degrees of
freedom.
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DA recent meta-analysis found that preoperative IABP de-
ployment may have a beneficial effect in specific high-risk
groups undergoing CABG.13 The randomized control trials
included in the meta-analysis had small treatment group
numbers (range, 30–60 patients) and notably were per-
formed in a single institution.14-18
Several nonrandomized studies have shown a survival
benefit with preoperative IABPs, especially with ‘‘off
pump’’ CABG.19-21 However, all these studies had included
a higher number of unstable high-risk patients in the inter-
vention arm, and ‘‘no difference in mortality’’ between the
2 groups was taken as a survival benefit in the intervention
group. Of the ‘‘on pump’’ studies, a few retrospective stud-
ies have found preoperative IABPs useful in high-risk pa-
tients.22,23 However, the intervention groups in these
studies had a higher number of unstable patients and patients
with unstable angina or recent myocardial infarction. An-
other large retrospective study that compared stable with un-
stable high-risk patients found that preoperative insertion of0.00
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FIGURE 1. Time to hospital discharge by timing of IABP insertion. IABP,
Intraaortic balloon pump; LOS, length of stay.
84 The Journal of Thoracic and Cardiovascular SurgeIABP conferred no survival benefit but was associated with
a reduced hospital length of stay.24.
A recent meta-analysis that included randomized trials
and cohort studies has supported the use of preoperative
IABPs in high-risk patients in terms of mortality benefit
and reduced ICU length of stay.9 Dyub and colleagues’
study9 found an increased hospital and ICU length of stay
with IABP use, especially in the postoperative group, which
conflicts with some previous reports.25,26 Differences in the
patient selection criteria in the included studies may account
for the result. Other possible reasons may be the increased
severity of illness in this patient group and also the IABP it-
self. The need to remain supine with an IABP predisposes
patients to atelectasis, pneumonia, and lower limb venous
thromboses. This review also found that the risk of compli-
cations (limb ischemia or hematoma) was low and reversible
with discontinuation and removal of the balloon (3.7%). Of
note, most included studies mentioned the use of 8F or larger
catheters. Therefore, there is potential to reduce complica-
tion rates further by using smaller-caliber catheters and
sheathless placement techniques. In our hospital, onlyTABLE 5. Predictors of use of intraoperative or postoperative
intraaortic balloon pump in those who did not receive a preoperative
intraaortic balloon pump
Variables Odds ratio (95% CI) Z P> jzj
Reoperation 3.5 (2.5–5) 7.22 .000
Creatinine>200 mmol/L 2.5 (1.4–4.4) 3.24 .001
Unstable angina 5.2 (3.1–8.6) 6.29 .000
EF<30% 9.5 (6.3–14.5) 10.53 .000
EF 30%–50% 2.3 (1.7–3.1) 5.23 .000
Recent MI 2.3 (1.6–3.2) 4.95 .000
Pulmonary hypertension 1.9 (1.3–3) 3.00 .003
1 valve only 0.6 (0.3–1.1) 1.68 .093
1 valveþCABG 2.3 (1.6–3.4) 4.41 .000
Complex surgery 2.3 (1.6–3.5) 4.12 .000
CI, Confidence interval; EF, ejection fraction; MI, myocardial infarction; CABG, cor-
onary artery bypass grafting.
ry c July 2010
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Dcatheters 7.5F and smaller are used now. Indeed, female pa-
tients (who predominantly received intraoperative or post-
operative IABPs) may perhaps benefit from having
a smaller sheathless catheter placed preoperatively, given
that female gender is a known risk factor for increased mor-
tality with CABG.
The postoperative group in our study had an in-hospital
mortality that, although comparable to the mortality rates
described in similar studies, was higher than other groups
in our study. This group requires further evaluation to deter-
mine whether an earlier or preoperative IABP placement
would improve outcomes. It is possible that this group expe-
rienced complications not recognized in the operative room.
The major disadvantages to IABP use thus far have been
complications associated with its placement, mainly bleeding,
vascular injury, and limb ischemia.11 Availability of smaller-
caliber 7F catheters and sheathless insertion techniques has
considerably reduced the incidence of vascular complications.
Furthermore, advances in IABP design, such as fiberoptic
technology, which provides higher fidelity arterial pressure
waveforms, elimination of need for repeated zeroing, and au-
tomatic trigger modes, have made day-to-day handling of bal-
loon pumps simpler, more accurate, and user-friendly.
This study also showed that it is possible to predict which
patients may require an intraoperative or a postoperative bal-
loon pump. This information may be useful in a long overdue
randomized trial of the timing of IABP insertion. Randomized
studies are needed to further delineate groups who would most
benefit from preoperative IABPs. Because the majority of ran-
domized studies in this area are from a single institution, there
is a need for an adequately powered multicenter study.
CONCLUSIONS
Preoperative IABP use was associated with a relative re-
duction in risk-adjusted mortality in this study. Our study
therefore supports the use of preoperative IABP in carefully
selected patients. Predictors of the need for an intraoperative
or a postoperative IABP were developed using simple,
widely available preoperative variables. This may assist in
the planning of a randomized study of preemptive IABP
use in high-risk patients.
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